Abstract
Background A 48-year-old man with a 9-year history of Parkinson's disease who had previously shown a good response to levodopa presented for evaluation of increasingly disabling motor fluctuations and marked camptocormia.
Investigations Video-recorded neurological examinations when in 'off' and 'on' states, brain MRI scan.
Diagnosis Advanced Parkinson's disease complicated by levodopa-responsive camptocormia.
Management Adjustment of dopaminergic therapy (carbidopa–levodopa and entacapone) to minimize motor fluctuations and camptocormia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Albanese A (2003) Diagnostic criteria for Parkinson's disease. Neurol Sci 24 (Suppl 1): S23–S26
Paulson H and Stern M (2004) Clinical manifestations of Parkinson's disease. In Movement Disorders: Neurologic Principles and Practice, edn 2, 233–246 (Eds Watts RL and Koller WC) New York: McGraw–Hill
Lepoutre AC et al. (2006) A specific clinical pattern of camptocormia in Parkinson's disease. J Neurol Neurosurg Psychiatry 77: 1229–1234
Azher SN and Jankovic J (2005) Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65: 355–359
Djaldetti R et al. (1999) Camptocormia (bent spine) in patients with Parkinson's disease—characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14: 443–447
Melamed E and Djaldetti R (2006) Camptocormia in Parkinson's disease. J Neurol 253 (Suppl 7): Svii14–Svii16
Sethi K (2003) Differential diagnosis of Parkinson's disease. In Handbook of Parkinson's Disease, edn 3, 43–70 (Eds Pahwa R et al.) New York: Marcel Dekker
Van Gerpen JA (2001) Camptocormia secondary to early amyotrophic lateral sclerosis. Mov Disord 16: 358–360
Zwecker M et al. (1998) Camptocormia: a case of possible paraneoplastic aetiology. Clin Rehabil 12: 157–160
Kiuru S and Iivanainen M (1987) Camptocormia, a new side effect of sodium valproate. Epilepsy Res 1: 254–257
Schabitz WR et al. (2003) Severe forward flexion of the trunk in Parkinson's disease: focal myopathy of the paraspinal muscles mimicking camptocormia. Mov Disord 18: 408–441
Horstink M et al. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13: 1170–1185
Watts RL et al. (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68: 272–276
Lang AE et al. (2006) Deep brain stimulation: preoperative issues. Mov Disord 21 (Suppl 14): S171–S196
Yamada K et al. (2006) Alleviation of camptocormia by bilateral subthalamic stimulation in a patient with Parkinson's disease. Parkinsonism Relat Disord 12: 372–375
Hellmann H et al. (2006) Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Mov Disord 21: 2008–2010
Micheli F et al. (2005) Camptocormia in a patient with Parkinson disease: beneficial effects of pallidal deep brain stimulation. Case report. J Neurosurg 103: 1081–1083
Acknowledgements
The patient is thanked for allowing publication of the photographs and supplementary online material, for which the patient's written consent was obtained.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B Ho and R Prakash declared no competing interests.
KD Sethi has received speaker's or consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Schwarz Pharma and Valeant, and has received research support from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Solvay, and Eisai.
JC Morgan has received speaker's or consultancy fees and research support from: Boehringer Ingelheim, GlaxoSmithKline and Novartis, and has received consultancy fees from Vernalis.
Supplementary information
Rights and permissions
About this article
Cite this article
Ho, B., Prakash, R., Morgan, J. et al. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease. Nat Rev Neurol 3, 526–530 (2007). https://doi.org/10.1038/ncpneuro0584
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0584